Trial Profile
A Randomised Placebo-controlled Trial of Anti-ST2 in COPD (COPD-ST2OP)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2023
Price :
$35
*
At a glance
- Drugs Astegolimab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms COPD-ST2OP
- 24 Feb 2021 Status changed from active, no longer recruiting to completed.
- 02 Sep 2020 Planned End Date changed from 7 Aug 2020 to 31 Dec 2020.
- 24 Jun 2020 Planned End Date changed from 31 May 2020 to 7 Aug 2020.